Accendra Health Suspended From NYSE, Moves to OTC Market Under ACCH

The company said trading in its common stock was suspended effective immediately and the NYSE will begin delisting proceedings, with shares now quoted on the OTCQB.

Stock reaction: ACH shares closed down 3.5% at $0.02 on Nov. 18, from Nov. 17's close of $0.02. The S&P 500 was down 0.3% that day.

scissors and syringes on a table of operating theater of a hospital conceptual image
Photo: Beyond This/Shutterstock.com

Key points

  • NYSE suspended trading in Accendra Health (NYSE: ACH) effective immediately and began delisting proceedings
  • Shares began trading on the OTCQB under ACCH on Nov. 17, 2026
  • The NYSE cited abnormally low selling price levels under Rule 802.01D
  • Q3 2026 net loss was $19.7 million, versus $150.3 million a year earlier
  • Cash and equivalents were $26.6 million as of Sept. 30, 2026

Accendra Health Inc. (NYSE: ACH) said the New York Stock Exchange suspended trading in its common stock and has started proceedings to delist it, according to an 8-K accepted Tuesday, Nov. 17, 2026. The company received the NYSE notice on Nov. 16.

The exchange based its decision on Rule 802.01D of the NYSE Listed Company Manual, citing abnormally low selling price levels, the press release filed with the 8-K said. Trading was suspended effective immediately.

Shares move to the over-the-counter market

The common stock began trading on the OTCQB market under the symbol ACCH on Nov. 17. The company said the move will not affect its business operations or its SEC reporting obligations, and does not conflict with or cause an event of default under any of its material debt or other agreements.

This is not the company's first exchange notice this fall. In an 8-K filed Oct. 30, Accendra disclosed an NYSE continued listing notice over market capitalization and stockholders' equity below $50.0 million. The forward-looking statements in the new press release refer to the company's ability to cure noncompliance with NYSE listing standards.

Losses narrowed in the latest quarter but remain large

For the third quarter ended Sept. 30, 2026, revenue was $601.8 million, down 14% from a year earlier. Operating income was $1.3 million, down 95%. The company reported a net loss of $19.7 million, compared with $150.3 million a year earlier, and a diluted loss of $0.25 a share against $1.94.

For the 2025 fiscal year, revenue was $2.76 billion, up 3%, but operating income was $27.5 million after an operating loss of $217.7 million the year before. The net loss was $1.10 billion, wider than the $362.7 million loss in 2024, and the diluted loss per share was $14.31 compared with $4.73.

Cash and equivalents totaled $26.6 million as of Sept. 30, 2026.

Management points to a turnaround

Chief Executive Kenny Gardner-Smith said in the release: "We are focused on taking the necessary steps and implementing decisive measures to support our turnaround and best position the Company for long-term growth and success." He added that the company continues to serve patients and customers and remains committed to its clinical conditions.

The filing does not give a timetable for completing the delisting or say how long the stock will trade on the OTCQB. Investors with questions were directed to Will Parrish, vice president of corporate development and investor relations, at Investor.Relations@accendra.com.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

ACH page →